dorsaVi Licenses NTU Robotics IP to Complete Full-Stack Robotics Platform
dorsaVi has secured exclusive rights to two key robotics patents from NTU Singapore, filling critical gaps in safety control and data acquisition to expand into collaborative robotics and exoskeleton markets.
- Exclusive 10-year license for NTU robotics IP
- New safety control framework enables real-time human-robot collaboration
- Data acquisition system converts clinical movement data into robot training sets
- Completes dorsaVi’s vertically integrated robotics intelligence stack
- Targets $17B collaborative robotics and $78B robotics AI software markets
Closing the Robotics Intelligence Gap
dorsaVi Limited (ASX:DVL) has taken a decisive step beyond wearable sensing with an exclusive license to two foundational robotics intellectual property assets from Nanyang Technological University Singapore (NTU). These patents address two longstanding challenges in collaborative robotics and exoskeleton development: ensuring mathematically rigorous safety controls for human-robot interaction and efficiently capturing real-world human movement data for robot training.
This license completes dorsaVi’s vision of a vertically integrated robotics intelligence platform, combining its existing clinically validated sensor technology and neuromorphic computing with newly acquired safety and data acquisition layers. The company now owns critical components from sensing and memory, through compute and control, to safety and learning, a rare end-to-end stack that positions it beyond component supplier status.
Two Robotics Inventions with Broad Applications
The first invention is a patented universal control framework that guarantees human safety in real time while enabling robots to perform complex tasks alongside people. Unlike conventional collaborative robots limited by simple force thresholds or proximity sensors, this framework uses control barrier functions and dynamic optimisation to maintain safety without sacrificing productivity. It aligns with evolving standards like ISO/TS 15066 and the EU AI Act, making it applicable across healthcare, manufacturing, defence, and exoskeleton systems.
The second invention is a multimodal data collection system designed to streamline the generation of high-quality, labelled training datasets for robotic AI. Leveraging dorsaVi’s existing clinical sensor networks, this system can turn validated human movement data into scalable robot learning libraries, enabling faster, more adaptive exoskeletons and cobots. This capability also opens opportunities for data-as-a-service offerings to third-party AI developers.
Strategic Expansion into High-Growth Markets
dorsaVi’s license broadens its addressable market into the global collaborative robotics sector, projected to exceed USD 17 billion by 2030, and the robotics AI software and data market, forecast to surpass USD 78 billion. Rehabilitation exoskeletons, a fast-growing medical robotics segment driven by ageing populations and neurological rehabilitation demand, are a priority vertical. The combination of clinically validated sensing, safety-assured control, and automated data pipelines creates a uniquely differentiated platform for exoskeleton development.
The company’s established clinical networks, including the SEROMA European study and Select Medical’s US physical therapy sites, provide immediate real-world environments for validating and commercialising these innovations. This clinical foothold also supports compliance with emerging European regulatory frameworks that emphasise on-device AI safety and data provenance.
Commercialisation and Financial Terms
dorsaVi plans to commercialise the NTU IP through licensing to industrial automation OEMs, offering data-as-a-service for robotics AI training, and partnering with medical robotics manufacturers on integrated exoskeleton solutions. The exclusive worldwide license spans ten years, with a total consideration of SGD 290,000 plus the issue of 5 million shares to Clayton Capital Pty Ltd. Notably, the deal carries no royalty payments on product sales.
CEO Mat Regan emphasised that this license is the culmination of a carefully sequenced strategy, building on recent milestones such as the validation of RRAM and neuromorphic chip technologies, the launch of a developer platform, and the commencement of hardware build programs. The NTU IP fills the last missing pieces, safety control and data intelligence, to complete dorsaVi’s robotics intelligence stack.
These developments dovetail with dorsaVi’s recent demonstration of significant battery life improvements in exoskeleton sensors through neuromorphic and RRAM integration, which could reduce sensor count and data transmission demands substantially, enhancing the viability of wearable robotics in demanding environments.
Bottom Line?
dorsaVi’s NTU IP license finalises its robotics platform, setting the stage for commercial partnerships and regulatory validation in fast-evolving collaborative robotics markets.
Questions in the middle?
- How quickly will dorsaVi convert this IP advantage into licensing deals with major cobot OEMs?
- Can the company scale its data-as-a-service offering to become a key AI training provider in robotics?
- What regulatory hurdles remain in Europe for deploying these safety and data technologies in medical exoskeletons?
